Prevention of hypertension with or without renin-angiotensin system inhibition precludes nephrin loss in the early stage of experimental diabetes mellitus

Nephron - Physiology

Volumn 107, Issue 2, 2007, Pages

  Amazonas, Roberto Bleuel ^a   De Almeida Sanita, Rodrigo ^a   Kawachi, Hiroshi ^b   Lopes De Faria, José B ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Albuminuria; Angiotensin receptor antagonist; Angiotensin converting enzyme inhibitor; Diabetic nephropathy; Hypertension; Nephrin; Spontaneously hypertensive rats

Indexed keywords

ANTIHYPERTENSIVE AGENT; CAPTOPRIL; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LOSARTAN; NEPHRIN; RESERPINE; STREPTOZOCIN;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; EXPERIMENTAL STUDY; GENE EXPRESSION; GENE LOSS; GLOMERULAR STRUCTURE; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; WISTAR KYOTO RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, EXPERIMENTAL; HYPERTENSION; MALE; MEMBRANE PROTEINS; RANDOM ALLOCATION; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RENIN-ANGIOTENSIN SYSTEM; TIME FACTORS;

EID: 35048900276     PISSN: 16602137     EISSN: None     Source Type: Journal    
DOI: 10.1159/000108642     Document Type: Article

References (33)

1. Schmitz A, Vaeth M, Mogensen CE: Systolic blood pressure relates to the rate of progression of albuminuria in NIDDM. Diabetologia 1994;37:1251-1258.
2. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-419.
3. Thomas MC, Atkins RC: Blood pressure lowering for the prevention and treatment of diabetic kidney disease. Drugs 2006;66:2213-2234.
4. Viberti GC, Mogensen CE, Groop LC, Pauls JF: Effect of captopril on progression to clinical proteinuria in patients with insulindependent diabetes mellitus and microal - buminuria. European Microalbuminuria Captopril Study Group. JAMA 1994;271:275-279.
5. Parving HH, Smidt UM, Hommel E, Mathiesen ER, Rossing P, Nielsen F, Gall M: Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis 1993;22:188-195.
6. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366:2026-2033.
7. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
8. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, for the Collaborative Study Group: Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
9. Brenner BM, Cooper ME, Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, for the RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
10. Strippoli GF, Graig M, Schena FP, Craig JC: Antihypertensive agents for primary prevention of diabetic nephropathy. J Am Soc Nephrol 2005;16:3081-3091.
11. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-1951.
12. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F: Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597-603.
13. Doublier S, Salvidio G, Lupia E, Ruotsalainen V, Verzola D, Deferrari G, Camussi G: Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003;52:1023-1030.
14. Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, Cao Z: Irbesartan normalizes the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 2001;44:874-877.
15. Righetti AE, Boer-Lima P, Lopes de Faria JB: The presence of genetic hypertension stimulates early renal accumulation of fibronectin in experimental diabetes. Diabetologia 2001;44:2088-2091.
16. Cooper ME, Rumble JR, Allen TJ, O'Brien RC, Jerums G, Doyle AE: Antihypertensive therapy in a model combining spontaneous hypertension and diabetes. Kidney Int 1992;41:898-903.
17. Silveira LA, Bacchi CE, Pinto GA, Lopes de Faria JB: The genetics of hypertension modifies the renal cell replication response induced by experimental diabetes. Diabetes 2002;51:1529-1534.
18. Amazonas RB, Lopes de Faria JB: Effects of tight blood pressure control on glomerular hypertrophy in a model of genetic hypertension and experimental diabetes mellitus. Life Sci 2006;79:2135-2143.
19. Davis BJ, Johnston CI, Burrell LM, Burns WC, Kubota E, Cao Z, Cooper ME, Allen TJ: Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy. Diabetologia 2003;46:961-971.
20. Davis BJ, Johnston CI, Burrell LM, Burns WC, Kubota E, Cao Z, Cooper ME, Allen TJ: Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Diabetologia 2004;47:89-97.
21. Pavan MV, Ghini B, Castro M, Lopes de Faria JB: Prevention of hypertension attenuates albuminuria and renal expression of fibronectin in diabetic spontaneously hypertensive rats. Am J Nephrol 2003;23:422-428.
22. Cooper ME, Allen TJ, O'Brien RC, Papazoglou D, Clarke E, Jerums G, Doyle AE: Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy. Diabetes 1990;39:1575-1579.
23. Lehfeld LS, Silveira LA, Ghini B, Lopes de Faria JB: Early blood pressure normalization independent of the class of antihypertensive agent prevents augmented renal fibronectin and albuminuria in experimental diabetic nephropathy. Kidney Blood Press Res 2004;27:114-120.
24. Orikasa M, Matsui T, Oite T, Shimizu F: Massive proteinuria induced in rats by a single intravenous injection of a monoclonal antibody. J Immunol 1988;141:807-814.
25. Bao L, Zhou J, Holers VM, Quigg RJ: Excessive matrix accumulation in the kidneys of MRL/lrp lupus mice is dependent on complement activation. J Am Soc Nephrol 2003;14:2516-2525.
26. Kawachi H, Koike H, Kurihara H, Yaoita E, Orikasa M, Shia MA, Sakai T, Yamamoto T, Salant DJ, Shimizu F: Cloning of rat nephrin: expression in developing glomeruli and in proteinuric states. Kidney Int 2000;57:1949-1961.
27. Clubb FJ, Bell PD, Kriseman JD, Bishop SP: Myocardial cell growth and blood pressure development in neonatal spontaneously hypertensive rats. Lab Invest 1987;56:189-197.
28. Imig JD, Falck JR, Gebremedhin D, Harder DR, Roman RJ: Elevated renovascular tone in young spontaneously hypertensive rats. Role of cytochrome P-450. Hypertension 1993;22:357-364.
29. Feld LG, Van Liew JB, Jens B Jr, Boylan JW: Renal lesions and proteinuria in the spontaneously hypertensive rat made normotensive by treatment. Kidney Int 1981;20:606-614.
30. Davis BJ, Cao Z, de Gasparo M, Kawachi H, Cooper ME, Allen TJ: Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. J Hypertens 2003;21:209-216.
31. Bonnet F, Tikellis C, Kawachi H, Burns WC, Wookey PJ, Cao Z, Cooper ME: Nephrin expression in the post-natal developing kidney in normotensive and hypertensive rats. Clin Exp Hypertens 2002;24:371-381.
32. Sung SH, Ziyadeh FN, Wang A, Pyagay PE, Kanwar YS, Chen S: Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 2006;17:3093-3104.
33. Anonymous: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Study Group. Br Med J 1998;317:703-713.